"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

“As long as APPs are properly supported, they will take off and they will change your practice,” says Mark T. Edney, MD. In this video, Mark T. Edney, MD, discusses how to foster a collaborative ...

TYRA-300's phase 2 trial in NMIBC aims to evaluate safety and efficacy, enrolling up to 90 patients with FGFR3 alterations. The primary endpoint is the complete response rate at 3 months, with ...

Sasanlimab combined with BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients compared to BCG alone. The CREST trial's results suggest potential paradigm shifts in ...

A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), ...

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias ...

“The key take home message of that study was that having assumptions about basic medical terminology that we think are simple may actually leave patients confused,” says Vikram M. Narayan, MD. In this ...

"The interplay between the microbiome and bladder cancer is very complex," says Ilaha Isali, MD, MSc. Isali: The interplay between the microbiome and bladder cancer is very complex. There is still ...

"Studying the microbiome overall is challenging because it's dirty science. You have to be incredibly careful with contamination," says Ilaha Isali, MD, MSc, and Laura Bukavina, MD, MPH, MSc. Isali: ...

Enfortumab vedotin and pembrolizumab combination significantly improves overall and progression-free survival in advanced urothelial carcinoma compared to platinum-based chemotherapy. The EV-302 trial ...

Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Nonmuscle Invasive Bladder Cancer Prior to recent therapeutic innovations in the bladder space what challenges or unmet ...

Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.